Scilex Holding Company Proceeds from Common Stock Issued
Scilex Holding Company (SCLX) reported Proceeds from Common Stock Issued of $1.10 million for the 1-month period ending 2024-12-31, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-14
- Scilex Holding Company proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- Scilex Holding Company proceeds from issuance of common stock for the quarter ending 2024-06-30 was $15.00M.
- Scilex Holding Company proceeds from issuance of common stock for the quarter ending 2024-03-31 was $10.00M, a 501.32% increase year-over-year.
- Scilex Holding Company proceeds from issuance of common stock for the quarter ending 2023-12-31 was $35.46M.
- Scilex Holding Company proceeds from issuance of common stock for fiscal 2023 was $35.46M.
- Scilex Holding Company proceeds from issuance of common stock for fiscal 2022 was $0.00.
- Scilex Holding Company proceeds from issuance of common stock for fiscal 2021 was $0.00.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 10 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $1.10M 10-Q · filed 2026-08-14 | ||||||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $15.00M derived: sum of 2 quarters · filed 2025-01-17 | $25.00M 10-Q · filed 2025-01-17 | $60.46M derived: sum of 4 quarters · filed 2025-01-17 | |||||
| 2024-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $25.00M 10-Q · filed 2024-08-13 | $60.46M derived: sum of 3 quarters · filed 2024-08-13 | $60.46M derived: sum of 4 quarters · filed 2025-01-17 | |||||
| 2024-03-31 | $10.00M 10-Q · filed 2024-05-13 | $45.46M derived: sum of 2 quarters · filed 2024-05-13 | $45.46M derived: sum of 3 quarters · filed 2025-01-17 | $43.80M derived: sum of 4 quarters · filed 2025-01-17 | |||||
| 2023-12-31 | $35.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $35.46M derived: sum of 2 quarters · filed 2025-01-17 | $33.80M derived: sum of 3 quarters · filed 2025-01-17 | $35.46M 10-K · filed 2024-03-12 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | -$1.66M derived: sum of 2 quarters · filed 2025-01-17 | $0.00 10-Q · filed 2025-01-17 | $27.59M 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-01-17 | ||||
| 2023-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $16.17M 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2024-08-13 | $0.00 derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $1.66M 10-Q · filed 2023-05-12 | $1.66M derived: sum of 2 quarters · filed 2024-03-12 | $1.66M derived: sum of 3 quarters · filed 2024-03-12 | $1.66M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 | |||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | -$135.60M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | -$135.60M derived: sum of 3 quarters · filed 2024-03-12 | -$135.60M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 | -$135.60M derived: sum of 2 quarters · filed 2024-03-12 | -$135.60M derived: sum of 3 quarters · filed 2024-03-12 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2021-12-31 | -$135.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$135.60M derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 | $135.60M 10-K · filed 2022-02-24 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $135.60M derived: sum of 2 quarters · filed 2022-11-04 | $135.60M 10-Q · filed 2022-11-04 | ||||||
| 2021-06-30 | $135.60M 10-Q/A · filed 2021-08-24 | $135.60M 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | $135.60M 10-Q · filed 2022-05-16 | ||||||||
| 2020-12-31 | $25.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |